Prevention, Early detection, Epidemiology, Tobacco control
49P - A Mendelian randomization study of the effects of Crohn’s disease on lung cancer
Authors
- J. Liu (Guangzhou, China)
- H. Zhou (Guangzhou, China)
- Y. Zhang (Guangzhou, China)
- W. Fang (Guangzhou, China)
- Y. Yang (Guangzhou, China)
- S. Hong (Guangzhou, China)
- G. Chen (Guangzhou, China)
- S. Zhao (Guangzhou, China)
- J. Shen (Guangzhou, China)
- W. Xian (Guangzhou, China)
- Y. Huang (Guangzhou, China)
- H. Zhao (Guangzhou, China)
- L. Zhang (Guangzhou, China)
Speakers
- J. Liu (Guangzhou, China)
Translational research
24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation
Authors
- P. Manca (Rome, Italy)
- I. Mallona (Zürich, Switzerland)
- D. Santini (Roma, Italy)
- G. Tonini (Roma, Italy)
- C. Rolfo (Baltimore, United States of America)
- M. Robinson (Zürich, Switzerland)
- F. Pantano (Roma, Italy)
Speakers
- P. Manca (Rome, Italy)
Locally advanced NSCLC
100P - A new PET-CT score for locally-advanced inoperable NSCLC stage III patients treated with chemoradiotherapy
Authors
- O. Roengvoraphoj (Munich, Germany)
- C. Eze (Munich, Germany)
- J. Taugner (München, Germany)
- A. Gjika (München, Germany)
- A. Tufman (Munich, Germany)
- L. Käsmann (Munich, Germany)
- I. Hadi (München, Germany)
- E. Mille (München, Germany)
- C. Belka (Munich, Germany)
- F. Manapov (Munich, Germany)
Speakers
- O. Roengvoraphoj (Munich, Germany)
Advanced NSCLC
183TiP - A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
Authors
- D. Planchard (Villejuif, France)
- B. Li (New York, NY, United States of America)
- H. Murakami (Shizuoka, Japan)
- R. Shiga (Tokyo, Japan)
- C. Lee (Basking Ridge, NJ, United States of America)
- K. Wang (Basking Ridge, NJ, United States of America)
- P. Jänne (Boston, MA, United States of America)
Speakers
- D. Planchard (Villejuif, France)
Advanced NSCLC
/thumbnails/0.png)
182TiP - A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
Authors
- P. Paik (New York City, NY, United States of America)
- A. Cortot (Lille, France)
- E. Felip (Barcelona, Spain)
- H. Sakai (Saitama, Japan)
- J. Mazieres (Toulouse, France)
- L. Horn (Nashville, TN, United States of America)
- F. Griesinger (Oldenburg, Germany)
- R. Bruns (Darmstadt, Germany)
- J. Scheele (Darmstadt, Germany)
- J. Straub (Darmstadt, Germany)
- R. Veillon (Pessac, France)
Speakers
- P. Paik (New York City, NY, United States of America)
Advanced NSCLC
133P - A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant
Authors
- J. Qu (Changsha, China)
- L. Liu (Changsha, China)
- J. Heng (Changsha, China)
- C. Zhou (Changsha, China)
- Y. Xiong (Changsha, China)
- W. Jiang (Changsha, China)
- N. Yang (Changsha, China)
Speakers
- J. Qu (Changsha, China)
SCLC
/thumbnails/0.png)
67TiP - ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer
Authors
- S. Senan (Amsterdam, Netherlands)
- N. Shire (Gaithersburg, United States of America)
- G. Mak (Gaithersburg, MD, United States of America)
- W. Yao (Gaithersburg, MD, United States of America)
- H. Jiang (Shanghai, China)
Speakers
- S. Senan (Amsterdam, Netherlands)
Advanced NSCLC
180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer
Authors
- J. Spicer (London, United Kingdom)
- M. Provencio (Madrid, Spain)
- P. Garrido Lopez (Madrid, Spain)
- J. Bosch-Barrera (Girona, Spain)
- F. De Castro Carpeño (Madrid, Spain)
- E. Felip (Barcelona, Spain)
- J. Trigo (Malaga, Spain)
- S. Viteri (Barcelona, Spain)
- E. Coart (Ottignies, Belgium)
- E. Schmidt (Kenilworth, NJ, United States of America)
- A. Christiansen (Copenhagen, Denmark)
- M. Zocca (Copenhagen, Denmark)
- M. Andersen (Copenhagen, Denmark)
- E. Ehrnrooth (Copenhagen, Denmark)
- L. Paz-Ares (Madrid, Spain)
Speakers
- J. Spicer (London, United Kingdom)
Advanced NSCLC
129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer
Authors
- Z. Lian (Suzhou, China)
- W. Du (Suzhou, China)
- J. Zhu (Suzhou, China)
- Y. Zeng (Suzhou, China)
- L. Zeyi (Suzhou, China)
- J. Huang (Suzhou, China)
Speakers
- Z. Lian (Suzhou, China)
Advanced NSCLC
155P - Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC)
Authors
- C. Saavedra Serrano (Madrid, Spain)
- A. Barquín García (Madrid, Spain)
- E. Corral de la Fuente (Madrid, Spain)
- J. Serrano Domingo (Madrid, Spain)
- V. Albarrán Artahona (Madrid, Spain)
- R. Martin Huertas (Madrid, Spain)
- A. Gómez Rueda (Madrid, Spain)
- M. Olmedo García (Madrid, Spain)
Speakers
- C. Saavedra Serrano (Madrid, Spain)
Advanced NSCLC
169P_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)
Authors
- E. Corral de la Fuente (Madrid, Spain)
- A. Barquín García (Madrid, Spain)
- C. Saavedra Serrano (Madrid, Spain)
- M. Olmedo García (Madrid, Spain)
- R. Martin Huertas (Madrid, Spain)
- J. Serrano Domingo (Madrid, Spain)
- V. Albarrán Artahona (Madrid, Spain)
- A. Gómez Rueda (Madrid, Spain)
Speakers
- E. Corral de la Fuente (Madrid, Spain)
Translational research
36P - Can a BALF profile distinguish hot vs cold lung tumors?
Authors
- J. Domagala-Kulawik (Warsaw, Poland)
- D. Dziedzic (Warsaw, Poland)
- M. Polubiec-Kownacka (Warsaw, Poland)
- T. Kryczka (Warsaw, Poland)
- I. Kwiecien (Warsaw, Poland)
Speakers
- J. Domagala-Kulawik (Warsaw, Poland)